|Bid||24.39 x 800|
|Ask||24.50 x 4000|
|Day's Range||23.96 - 24.63|
|52 Week Range||12.32 - 28.86|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||27.20|
The South San Francisco company is putting its IPO where its mouth is — hoping to take its lead drug, targeting a tooth-loss-causing bacteria that migrates from the mouth to the brain, into a Phase II/III clinical trial soon.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can significantly boo...
OUTSIDE THE BOX Here are four stocks to watch with strong price momentum fueled by earnings. Denali Therapeutics Inc. (DNLI) jumped $2.17 to $24.37 on 1.19 million shares Wednesday, nearly three times its average volume.
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 4050.00% and 1191.24%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
SOUTH SAN FRANCISCO, Calif., March 12, 2019 -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for.
NEW YORK, Feb. 19, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
“We are excited to advance DNL747 in a second neurodegeneration indication based on Phase 1 healthy volunteer data regarding DNL747’s safety profile, CNS penetration, and target engagement, at the studied doses.” said Carole Ho, M.D., Chief Medical Officer of Denali. “Similar to our previously announced Phase 1b study in ALS, the primary purpose of this Phase 1b study is to gain additional safety and biomarker data in patients with Alzheimer’s disease to support dose selection.
Genentech's Alzheimer's-fighting drug failed two late-stage studies, but other Bay Area companies are continuing with different approaches to the memory-stealing disease.
“Based on Phase 1 data in healthy volunteer subjects demonstrating DNL747’s excellent CNS penetration, safety profile, and ability to inhibit the RIPK1 pathway, we are excited to evaluate DNL747 in ALS patients,” said Carole Ho, M.D., Chief Medical Officer of Denali. “The primary purpose of this Phase 1b study is to gain additional safety and biomarker data in ALS patients to support dose selection.
“Based on the positive outcome of our Phase 1 study in 122 healthy volunteer subjects, we are excited to evaluate DNL201 in Parkinson’s disease patients,” said Carole Ho, M.D., Chief Medical Officer of Denali. “This study will provide additional important safety and biomarker data in patients to support rational dose selection.
Biotech stocks pulled back in last week. Incidentally, some large-cap biotech stocks were hitting new peaks even amid the sectoral downturn. New molecular entity approval hit a new peak at 55 thus far ...
Why a South Bay company thinks it can disrupt a tough antibiotics market — and more in our weekly Health Care Digest.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 19) Merck & Co., Inc. (NYSE: MRK ) Down In The Dumps (Biotech ...
Denali Therapeutics Inc. (DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced positive results from its Phase 1 healthy volunteer study of DNL747, a brain penetrant small molecule inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1). RIPK1 is a critical signaling protein in the tumor necrosis factor receptor pathway and is a regulator of inflammation and cell death in tissues throughout the body. Denali recently announced a broad collaboration with Sanofi on the development of multiple RIPK1 inhibitor molecules, including DNL747, to study their potential to treat a range of neurological and systemic inflammatory diseases.
One of the first tenants in The Cove at Oyster Point is taking the last building in the South San Francisco development as rents in the region hit new highs.
SOUTH SAN FRANCISCO, Nov. 08, 2018 -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 1) Merck & Co., Inc. (NYSE: MRK )(announced FDA approval ...
Candidate RIPK1 inhibitor molecules have the potential to treat Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and systemic inflammatory.
Dallas’ largest hedge funds have placed their longest bets on publicly traded companies in a variety of industries, from technology and utilities to health care and social media behemoths, according to an analysis of their most recent regulatory filings.
CENTOGENE and Denali Therapeutics (DNLI) today announced a strategic collaboration for the global identification and recruitment of LRRK2 mutation carrier Parkinson’s disease (“PD”) patients. CENTOGENE will conduct a targeted global recruitment campaign focused on the early identification and characterization of LRRK2 PD patients and sequence the LRRK2 gene in these patients. Under the terms of the agreement, CENTOGENE will utilize CentoCard®, its proprietary, validated, dried blood spot collection kit, to identify PD patients with a mutation in the LRRK2 gene for recruitment into Denali’s clinical trials.
If you want to know who really controls Denali Therapeutics Inc (NASDAQ:DNLI), then you’ll have to look at the makeup of its share registry. Generally speaking, as a company grows,Read More...